Agenda
13-16 October 2025
RAI Congress Centre, Amsterdam
Amsterdam, 13 - 16 October 2025
Schedule
Create your personal agenda –check the favourite icon
Oct 1310:00
Conference pass
Platform Technologies Workshop [AM1]
Platform Technologies Workshop
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group
Robbert Van der Most, CEO, Vaxxcellence
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Session led by: 
Session led by: 
Session led by: 
Merijn Salverda, Scientist Bacterial Vaccines, Intravacc
Oct 1310:00
Conference pass
Biothreats & Disease X Workshop [AM2]
Biothreats & Disease X Workshop
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Swati Gupta, VP, Head of Emerging Infectious Diseases and Epidemiology, International AIDS Vaccine Initiative
Lucy Chappell, Chief Scientific Adviser, UK Department of Health and Social Care
Oct 1313:00
Conference pass
Lunch & Networking Break
Exhibition & Networking
Afternoon Workshops Begin at 2pm:
- Vaccine Safety
- Vaccine Delivery
- Special Populations
Oct 1314:00
Conference pass
Vaccine Safety Workshop [PM1]
Vaccine Safety Workshop
Peter Aaby, Professor & Founder, Bandim Health Project
Session led by: 
Debabrata Roy, VAC4EU Executive Board Member, Drug Safety Research Unit
Miriam Sturkenboom, Professor in RWE & Head, Department of DataScience and Biostatistics, University Medical Center Utrecht & President, Vac4eu
Oct 1314:00
Conference pass
Special Populations Workshop [PM2]
Special Populations Workshop
Kirsten Maertens, Assistant Professor, Vaccines & Infectious Disease Institute, University of Antwerp
Rosa Gini, Vice President and Head of the Pharmacoepidemiology Unit, Vac4eu
Mark Newman, Chief Scientific Officer, GeoVax
Oct 1314:00
Conference pass
Vaccine Delivery Workshop [PM3]
Vaccine Delivery Workshop
Create your personal agenda –check the favourite icon
Oct 149:00
Conference pass
Beyond Borders: Europe’s Strategic Role in Powering Vaccine Innovation and Transforming the Global Vaccine Landscape
Keynotes
- How can Europe’s unique ecosystem of innovation hubs, regulatory frameworks, and public-private partnerships accelerate the next generation of breakthrough vaccines?
- What strategies and incentives are needed to transform Europe’s emerging biotechs and SMEs into tomorrow’s vaccine innovation leaders?
- How can regulatory frameworks evolve to support rapid innovation while maintaining the gold standard in vaccine safety and efficacy?
- In an increasingly complex global health landscape, how can Europe balance domestic innovation priorities with its responsibility to ensure equitable worldwide vaccine access?
Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)
Oct 1410:00
Conference pass
Rebuilding Public Literacy and Trust in an Era of Polarisation and Political Uncertainty
Keynotes
- The global impact of U.S. vaccine policy shifts: how political narratives in the U.S. are impacting vaccine confidence and policies worldwide
- The role of governments, media, and public health leaders: what tangible steps can be taken to counter vaccine scepticism and rebuild trust in science?
- What evidence-based strategies are actually working to rebuild trust and increase vaccine uptake in highly polarised environments?
- Tailoring communication approaches to address vaccine hesitancy in different cultural, socioeconomic, and political contexts
- In an increasingly fragmented world, how can we build sustainable cross-border collaborations to strengthen vaccine confidence and literacy?
- AI, trust & biosecurity
Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network
Seth Ginsberg, Co-Founder and President, Global Healthy Living Foundation
Oct 1411:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1411:30
Conference pass
Working Group 1: Introduction to the Korean ARPA-H Initiative: STOREx & DeCAFx
Working Groups
Manki Song, Deputy Director General of Science, International Vaccine Institute
Jae Myun Lee, Scientific Advisor, QuadMedicine, Inc.
Oct 1411:30
Conference pass
Working Group 2: Adoption and utilization of virus neutralization assays: Challenges and best practices
Working Groups
Session led by: 
Oct 1411:30
Conference pass
Working Group 4: Rising Stars: Empowering Mid-Career Women in Global Immunisation Leadership
Working Groups
- What challenges do mid-career women face when transitioning into leadership roles in immunisation?
- How can we support professional growth and visibility for women in vaccine R&D and policy?
- Lessons from Women Lift Health & other networks
- How do gender representation and equity shape immunisation policy and leadership?
- Mentorship and networking strategies for career advancement
- Balancing field experience with leadership aspirations
Oct 1412:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1412:40
Conference pass
Start-Up Pitches
Start-Up Pitches
12:40 - Dr Benjamin Damien , CEO, Sagitta Biotech
12:45 -Comprehensive Immunopeptidomics Platform for Vaccine Development and Construct Validation - Dr Elise Pepermans, CEO, ImmuneSpec
12:50 - Dr Vanessa Vankerckhoven, CEO, Idevax
12:55 - Daniel Becker, Head of Business Development, KyooBe Tech
13:00 - Bruno Vandelanotte, Head of EMEA Sales, Roncadelle Operations
13:05 - Maite Segurola, Head Of Life Science, Cocoon Bioscience
13:10 - Start-Up Pitch Feedback Panel
Benjamin DAMIEN, CEO, Sagitta Biotech
Vanessa Vankerckhoven, CEO, IDEVAX
Daniel Becker, Head of Business Development INACTIVATE, KyooBe Tech GmbH
Bruno Vandelanotte, Sales Manager EMEA, Roncadelle-Operations
MAITE SEGUROLA, HEAD LIFE SCIENCES PORTFOLIO, Cocoon Bioscience
Thom Frielink, Associate, Curie Capital BV
Start-Up and Showcase Stage
Oct 1414:00
Conference pass
Capturing high quality immunoassay data- case studies using Certimmune
Technology Showcases
Session led by: 
Oct 1414:00
Conference pass
Capillary Devices for Sample Collection in Decentralized Vaccine Studies
COVID & Beyond
Session led by: 
Oct 1414:00
Conference pass
COVID & Beyond Track Chair
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1414:00
Conference pass
A new animal-free recombinant enzyme for cell-based vaccine production
Formulation & Bioprocess
Session led by: 
Oct 1414:00
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Oct 1414:00
Conference pass
AMR Funding & Partnerships
AMR & Bacterial Vaccines
Senior Representative, Bactivac
Oct 1414:00
Conference pass
Immunogenicity assays for rapid response to emerging viral pathogens
Pre-Clinical Development
Session led by:
Oct 1414:00
Conference pass
Immunofocusing: How to drive focused or broad antibody responses for optimal vaccine protection
Immune Profiling
Oct 1414:15
Conference pass
Advanced Technologies in Animal-Free Viral Vaccines Production
Technology Showcases
Session led by: 
Oct 1414:30
Conference pass
GMP NGS for Quality Control Testing of Vaccines
Technology Showcases
Session led by: 
Oct 1414:30
Conference pass
Scaling new heights: ionizable lipids for vaccine development, GMP manufacturing, and clinical success
COVID & Beyond
Session led by: 
Oct 1414:30
Conference pass
Ensuring clinical availability of vaccine delivery systems, immunostimulators & combined adjuvant systems
Formulation & Bioprocess
Session led by: 
Oct 1414:30
Conference pass
Advancing Vaccines and Antibodies for Drug-Resistant Infections
AMR & Bacterial Vaccines
- The role of both vs a vs “traditional” antibiotics
- What is in the pipeline / where are the gaps
- Barriers and opportunities to stimulate R&D
Hester Kuipers, Exec Director Europe, IAVI
Oct 1414:30
Conference pass
Developmental and Reproduction Toxicity (DART) Assessment for Vaccines
Pre-Clinical Development
Session led by: 
Oct 1414:30
Conference pass
Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays
Immune Profiling
Session led by: 
Oct 1414:45
Conference pass
Needle-Free, Cold Chain–Independent Vaccines via Electro-hydrodynamic Processing
Formulation & Bioprocess
Session led by: 
Jose Maria Lagaron, Founder, CEO & CSO, BIONANOPHARMA
Oct 1414:45
Conference pass
Title TBC
Pre-Clinical Development
Session led by: 
Oct 1414:45
Conference pass
AI-enabled immune-profiling to accelerate vaccine development
Immune Profiling
Oct 1415:00
Conference pass
Title TBC
COVID & Beyond
Session led by: 
Oct 1415:15
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1415:45
Conference pass
A scalable cell-free protein production technology accelerating vaccine development
Technology Showcases
Session led by: 
Oct 1415:45
Conference pass
COVID & Beyond Track Chair
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1415:45
Conference pass
Harnessing Microbial Innovation: The Road to a First-in-Human pan-Sarbecovirus Vaccine
COVID & Beyond
Oct 1415:45
Conference pass
Clinical Data on New Adjuvant AS37, a TLR7 Agonist
Formulation & Bioprocess
Marguerite Koutsoukos, Sr Clinical Science Lead, GSK
Oct 1415:45
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Oct 1415:45
Conference pass
Correlates of protection in the CoV002 trial of ChAdOx1.nCOV19 (Vaxzevria): A Systems Serology analysis
Immune Profiling
Session led by: 
Ashley Brate, SeromYx
Oct 1416:00
Conference pass
Thermostability: Formulations That Bridge All Modalities
Technology Showcases
Session led by: 
Oct 1416:00
Conference pass
The Next Coronaviruses as Possible Pandemic Threats
COVID & Beyond
Kayvon Modjarrad, Executive Director, Viral Vaccines, Pfizer
Oct 1416:00
Conference pass
Adjuvants Panel
Formulation & Bioprocess
Nicolas Collin, Co-Founder and Chief Executive Officer, Vaccine Formulation Institute CH Ltd
Oct 1416:00
Conference pass
From Farm to Fish: Species-Specific Strategies to Reduce Antibiotic Use in Livestock and Aquaculture
AMR & Bacterial Vaccines
- The role of combination vaccines and new vaccine platforms in preventing bacterial infections
- Case studies of successful vaccine interventions that led to measurable reductions in antibiotic use.
- Management and biosecurity strategies: recent progress in biosecurity protocols and livestock management practices
- Global standards and coordination efforts for AMR control in livestock.
- Species specific approaches: poultry, swine, aquaculture
- New vaccine platforms and combination approaches in veterinary health
- Biosecurity protocols and best practices for AMR control
David Farcas, Director, Chile, Yelcho
Ivo Claassen, Head of Veterinary Medicines Division, EMA
Oct 1416:00
Conference pass
Electron Microscopy Mapping of Antibodies
Pre-Clinical Development
Oct 1416:15
Conference pass
A circular RNA vaccine to treat infectious and other diseases
Technology Showcases
Session led by: 
Peter Weinstein, Chief Executive officer, Emervax
Oct 1416:15
Conference pass
The Role of Cellular Immunity in COVID-19 Vaccination: New Insights and Applications
COVID & Beyond
Oct 1416:15
Conference pass
Computational Approaches to Antigen Design & Immunofocusing
Pre-Clinical Development
Oct 1416:15
Conference pass
Trained Immunity
Immune Profiling
Robbert Van der Most, CEO, Vaxxcellence
Oct 1416:30
Conference pass
Candidate Vaccines for MERS-CoV and Related Merbecoviruses
COVID & Beyond
Oct 1416:30
Conference pass
Title TBC
Immune Profiling
Session led by: 
Oct 1416:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1417:00
Conference pass
AMR: Promoting the alignment of nation action plans and implementation of vaccination strategies across human and animal health
Keynotes
- How do we begin implementing the commitments of the political declaration?
- What are our priority areas and diseases where vaccination can mitigate and prevent AMR?
- Ensuring a multisectoral approach: where will human and animal sectors align and collaborate on their strategies?
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Create your personal agenda –check the favourite icon
Oct 159:00
Conference pass
Rethinking Global Health Threats and Responses: H5N1, Mpox, Measles, Marburg, Climate, Zoonoses, and Emerging Risks
Keynotes
- Pandemic vs. endemic priorities: What’s missing from the global agenda? – Are we too fixated on future pandemics while ignoring the growing threats of endemic infectious diseases (e.g., TB, dengue, H5N1)?
- Climate-driven disease risks: Are we accurately predicting which pathogens will surge due to climate change? (e.g., vector-borne diseases like malaria vs. less-discussed threats). How can we better anticipate less obvious threats?
- How should we be investing in surveillance and R&D? – What innovations (AI, genomics, forecasting) actually have the potential to get ahead of the next crisis?
- How do we ensure that disease prioritisation is driven by science, not politics? – What structural and policy shifts are needed to avoid repeating past mistakes?
- Are we adequately investing in diagnostic capabilities for future threats, or are we overly focused on vaccines and treatments? How can improved diagnostic strategies enhance our ability to detect and respond to emerging threats quickly?
- How can we improve international collaboration in disease surveillance, research, and response while addressing geopolitical challenges and ensuring equitable access to resources?
Wolfgang Philipp, Principal Adviser, Chief Science Officer, European Commission Health Emergency Preparedness & Response (HERA)
Oct 1510:00
Conference pass
Valuing Vaccines Beyond Cost-Effectiveness
Keynotes
- How can we evolve beyond traditional metrics to capture the full societal value of vaccines - from pandemic prevention to economic stability?
- What would a new multidimensional framework for measuring vaccine impact look like, and how could it transform funding priorities?
- How do we bridge the gap between theoretical frameworks and real-world policy adoption - what are the barriers and opportunities?
- As the world faces new health challenges, how can expanded valuation metrics help drive better decision-making in vaccine development and implementation?
Oct 1511:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1511:30
Conference pass
Engineering a Medical Device for Intranasal Immunization: Ensuring Targeted Delivery and Formulation Stability
AMR & Bacterial Vaccines
Oct 1511:30
Conference pass
Clinical Development Driven by Epidemiological Research
Clinical Trials
Session led by: 
Oct 1511:30
Conference pass
Clinical Trials Track Chair
Clinical Trials
Oct 1511:30
Conference pass
Highly pathogenic avian influenza - the deadly hitchhiker around the Globe
One Health & Veterinary
Session led by: 
Oct 1511:30
Conference pass
One Health & Veterinary Track Chair
One Health & Veterinary
Oct 1511:30
Conference pass
Oct 1511:30
Conference pass
Using challenge studies to eliminate the problem of low virus circulation or strain evolution in vaccine efficacy testing
Respiratory
Session led by: 
Oct 1511:30
Conference pass
Emerging & Infectious Diseases Track Chair
Emerging & Infectious Diseases
Michel De Wilde, Former Senior Vice President R&D Of Sanofi Pasteur & Owner, MDW Consultant LLC
Oct 1511:30
Conference pass
Emerging & Infectious Diseases Track Chair
Emerging & Infectious Diseases
Michel De Wilde, Former Senior Vice President R&D Of Sanofi Pasteur & Owner, MDW Consultant LLC
Oct 1511:30
Conference pass
Integrating Diagnostics and Surveillance in Advancing Disease Burden Estimation
Emerging & Infectious Diseases
Oct 1511:30
Conference pass
Translating Outer Membrane Vesicles (OMVs) from Research to Clinical Manufacturing: Overcoming Challenges and Unlocking Vaccine Potential
Bioprocess & Manufacturing
Session led by: 
Ola Tuvesson, Chief Technology Officer, NorthX Biologics
Oct 1511:35
Conference pass
How can a microneedle manufacturer contribute to the success of cancer vaccine developers?
Biopharma Showcases
Session led by: 
Oct 1511:45
Conference pass
The Microbiome's Role in Infection Prevention: A New Frontier in CHIM Trials
Clinical Trials
Session led by: 
Oct 1511:45
Conference pass
Oral bivalent vaccine for norovirus protection. Recent improvements to improve immunogenicity and potentially efficacy
Emerging & Infectious Diseases
Session led by: 
Oct 1511:45
Conference pass
Preclinical Studies on a Single-Administration HIV mRNA and Protein Trimer Vaccine Utilizing Long-Acting Silica Matrix Technology
Biopharma Showcases
Session led by: 
Oct 1511:45
Conference pass
Introduction of Commercially Relevant, Ready to Use, High Value Vaccine Adjuvant Systems
Bioprocess & Manufacturing
Session led by: 
Oct 1512:00
Conference pass
Raising effective immunity against bacterial Outer-Membrane Proteins with a whole-cell platform: universal and multi-pathogen vaccines
AMR & Bacterial Vaccines
Oct 1512:00
Conference pass
Clinical Supplies Logistics for Global Mega Vaccine Trials
Clinical Trials
Oct 1512:00
Conference pass
C1 Technology: Redefining Biomanufacturing for a Healthier Tomorrow- Accelerating the Scalable, Cost-Effective Production & Release of Antigens, Antibodies & Enzymes
Respiratory
Session led by: 
Oct 1512:00
Conference pass
Title TBC
Emerging & Infectious Diseases
Session led by: 
Oct 1512:00
Conference pass
One Size Doesn't Fit All: Modular Strategies for Viral Vector Fill & Finish Operations
Bioprocess & Manufacturing
Session led by: 
Stefania Di Marco, QP & Director of Quality Control, Advent Srl
Oct 1512:15
Conference pass
Technological Advancements in Veterinary Vaccines
One Health & Veterinary
Oct 1512:15
Conference pass
Diverse Applications of Vero Cells for Viral Vaccines and Viral Vectors in Chemically Defined Conditions
Bioprocess & Manufacturing
Session led by:
Oct 1512:30
Conference pass
Vaccine progress towards Group A Strep
AMR & Bacterial Vaccines
Oct 1512:30
Conference pass
Factors and strategies impacting recruitment and retention in vaccine trials
Clinical Trials
Session led by: 
Oct 1512:30
Conference pass
Advancing Influenza Prevention: Latest Clinical Insights on OVX836, a Broad-spectrum T-Cell Influenza Vaccine
Respiratory
Session led by: 
Oct 1512:30
Conference pass
AI-based target discovery for infectious disease vaccines
Emerging & Infectious Diseases
Session led by: 
Oct 1512:30
Conference pass
Ensuring Quality and Compliance in Bioprocessing: Biosafety and GMP Solutions for Advanced Biologic Production
Bioprocess & Manufacturing
Session led by: 
Oct 1512:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1513:00
Conference pass
Start-Up Pitches
Start-Up Pitches
13:00 - Markus Mandler, CEO & Founder, Tridem Bioscience
13:05 - Jenni Vuola, Buisness Devlopment Advisor, Rokote Laboratories Finland
Start-Up and Showcase Stage
Oct 1514:15
Conference pass
Clinical Trials Track Chair
Clinical Trials
Oct 1514:15
Conference pass
One Concept, Many Realities: Dimensions of Real-World Evidence in Practice
Clinical Trials
Session led by: 
Duco Veen, Manager, Julius Clinical
Oct 1514:15
Conference pass
Between ethics and urgency; the role of non-humane primates in vaccine research
One Health & Veterinary
Merel Langelaar, Director, Biomedical primate research centre
Session led by: 
Oct 1514:15
Conference pass
Panel: Why has flu vaccine efficacy stalled and how do we fix it?
Respiratory
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group
Roland Zahn, Senior Scientific Director, Head Nonclinical and Translational Immunology & Biomarkers, CDTL Universal Influenza Vaccine & CDTL, Johnson & Johnson
Oct 1514:15
Conference pass
Oct 1514:15
Conference pass
A Novel, Single-dose, Live, Attenuated, Minimally Replicating Mpox Vaccine
Emerging & Infectious Diseases
Session led by: 
Zeil Rosenberg, Executive Vice President, Medical, Tonix Pharmaceuticals
Oct 1514:15
Conference pass
Vaccine formulation for needle-free delivery via microneedle array patches
Bioprocess & Manufacturing
Session led by: 
Oct 1514:45
Conference pass
Updates on Vaccine Development for E.Coli: ETEC Phase IIb data in travellers and endemic populations
AMR & Bacterial Vaccines
Oct 1514:45
Conference pass
Veterinary regulatory developments and innovations: experiences with implementation
One Health & Veterinary
Ivo Claassen, Head of Veterinary Medicines Division, EMA
Oct 1514:45
Conference pass
From Kit to Custom: Development of an Accurate In-House Host Cell DNA and Sizing Assay
Bioprocess & Manufacturing
Session led by: 
Oct 1515:00
Conference pass
Updates on Vaccine Development for Klebsiella
AMR & Bacterial Vaccines
Simona Rondini, Head Bacterial Projects and Senior Project Leader, GSK Vaccines
Oct 1515:00
Conference pass
Vaccine Correlation using Tasso Capillary Device
Clinical Trials
Session led by:
Oct 1515:00
Conference pass
Oct 1515:15
Conference pass
Next-generation vaccine development and therapeutic antibodies for bacterial pathogens
AMR & Bacterial Vaccines
Fadil Bidmos, Associate Professor in Bacterial Vaccinology, Imperial College London
Oct 1515:15
Conference pass
Field Implementation Strategies in Wildlife and Livestock
One Health & Veterinary
- Practical aspects of wildlife vaccination programmes: oral bait for ASF in wild boar/feral pigs, lessons from classical swine fever control
- Surveillance strategies and challenges; overcoming practical and ethical challenges in wildlife sampling, balancing active vs. passive surveillance, UK bat surveillance for rabies (APHA Weybridge)
- Evolution of vaccine profiles from containment to eradication stages
- Role of DIVA strategies in eradication programs
- Case study: PPR vaccine transition from live to killed vaccines
Oct 1515:15
Conference pass
Title TBC
Emerging & Infectious Diseases
Oct 1515:15
Conference pass
Thermostable cRNA-VLP and VLP Vaccine using the D-Crypt™ Platform: Revolutionizing Vaccine Production and Delivery
Bioprocess & Manufacturing
Session led by: 
Oct 1515:30
Conference pass
LTB-SA7, a multicomponent toxoids vaccine against S. sureus in phase I
AMR & Bacterial Vaccines
Oct 1515:30
Conference pass
Controlled Human Infection Models in Drug Development
Clinical Trials
Oct 1515:30
Conference pass
Preclinical and clinical progress on Clover’s RSV stand alone and RSV hMPV PIV3 trivalent combination vaccines
Respiratory
Session led by: 
Oct 1515:30
Conference pass
Optimizing Downstream Processing for Next-Generation Vaccine Development
Bioprocess & Manufacturing
Session led by: 
Maja Leskovec, Head of PD viruses, Bia Separations
Oct 1515:45
Conference pass
Conjugate Vaccines for AMR: Advancing Chemistry and Expanding Pathogen Coverage
AMR & Bacterial Vaccines
- Explore new developments in conjugate vaccine chemistry, including click chemistry and novel formulations.
- Highlight the clinical success and market impact of high-valent conjugate vaccines targeting bacterial pathogens such as pneumococcal formulations.
- The role of conjugate vaccines in reducing bacterial infections and antibiotic use, contributing to AMR mitigation.
- Discuss future directions and opportunities for high-valency conjugate vaccine development in addressing diverse pathogens of AMR-priority status
Oct 1515:45
Conference pass
Oral Covid Vaccine - Clinical Update from phase 1 to phase 2B
Respiratory
Session led by:
Oct 1515:45
Conference pass
Comparative analysis of evidence generation approaches for vaccines in outbreak settings
Emerging & Infectious Diseases
- Significant progress in research on arboviruses and flaviviruses; dengue, tick-borne encephalitis, yellow fever
- Evolving regulatory approaches for trials, adapting to new technologies and global health challenges
- Chikungunya case study; navigating multi-country licensure challenges and innovative regulatory approaches
- Evidence generation under pressure; balancing urgent public health needs with trial rigour
- Post-licensure trials in non-licensed markets; regulatory, ethical and operational complexities
- How global regulators are evolving approaches to support both emergency responses and robust scientific evaluation during outbreaks
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
Jakob Cramer, Head Of Clinical Development, CEPI
Oct 1516:00
Conference pass
Non-Technical Barriers to Vaccine Adoption in Livestock and Companion Animals
One Health & Veterinary
Nathaniel Whitley, Vaccination Committee, World Small Animal Veterinary Association
Oct 1516:00
Conference pass
Maternal Vaccination & Immunogenicity Data
Respiratory
Kirsten Maertens, Assistant Professor, Vaccines & Infectious Disease Institute, University of Antwerp
Oct 1516:00
Conference pass
Transforming Vaccine Development and Manufacturing: Integrating Technology and Accessibility for a Healthier 21st Century
Bioprocess & Manufacturing
Session led by: 
Oct 1516:15
Conference pass
Serological assays: a tool for vaccine evaluationa and pandemic preparedness
Clinical Trials
Session led by: 
Oct 1516:30
Conference pass
Improving Clinical Trial Recruitment
Clinical Trials
Session led by: 
Oct 1516:30
Conference pass
Oct 1516:30
Conference pass
Development, Scale-Up, and Manufacture of an Oncolytic Virus Vaccine
Bioprocess & Manufacturing
Session led by: 
Oct 1516:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1517:00
Conference pass
Frontier Technologies in Vaccine Innovation: What are the market trends and how is innovation addressing evolving health threats
Keynotes
- How does the current pipeline look and what types of vaccines can we anticipate?
- The importance of diversity in technologies
- How is AI-driven vaccine design, ML, Synthetic biology, engineering antigens, and novel delivery systems changing the way develop vaccines?
- Personalised vaccinology; examining the future of individualised vaccines
- Dual Markets & Sustainability: Managing the LMIC-HIC divide while pushing for eco-friendly design and novel vaccines
Jerome Kim, Director General, ivi
Jean-Pierre Amorij, Vaccine Technology Specialist, UNICEF
Create your personal agenda –check the favourite icon
Oct 169:00
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 169:30
Conference pass
Clinical Trials Track Chair
Clinical Trials
Oct 169:30
Conference pass
The Vaccine Innovation Pathway: The UK’s First Clinical Trial Delivery Accelerator
Clinical Trials
Maria Koufali, Programme Director, UK Vaccine Innovation Pathway
Oct 169:30
Conference pass
Introduction to the Korean ARPA-H Initiative - Infectious Disease Vaccine Research Programs: STOREx & DeCAFx
Manufacturing Technologies
Advancing Vaccine Innovation and Preparedness through the Korean ARPA-H Initiative
Session led by: 
Kevin Kee-Jong Hong, Professor, K-Health MIRAE (Korea ARPA-H, former KmVAC)
Oct 169:30
Conference pass
A Guide to Valuation for Fundraising
Partnerships & Access
Oct 169:30
Conference pass
Compliance in supply chain & logistics operations: make or break your clinical trial
Supply & Logistics
Session led by: 
Oct 169:30
Conference pass
The Source of Saponin Adjuvants: QS21 - Approved, Available, and Abundant
Supply & Logistics
Session led by: 
Oct 169:30
Conference pass
UK Cancer Vaccine Launchpad
Cancer & Therapeutic Vaccines
Oct 169:45
Conference pass
Korea's Health Initiative to address unmet medical needs: Investing in a platform for Personalized Cancer Vaccine development
Manufacturing Technologies
Advancing Vaccine Innovation and Preparedness through the Korean ARPA-H Initiative
Younbeen Kim, Project Manager, Health Security, K-Health MIRAE Initiative
Oct 1610:00
Conference pass
Taking a multi-antigen vaccine into clinical trials
Clinical Trials
Oct 1610:00
Conference pass
MANGO: Automating VLP Production Using Cell-Free Expression Technology
Manufacturing Technologies
Oct 1610:00
Conference pass
The Role of Incubators & Funding Models in Advancing Vaccine Development
Partnerships & Access
Jonathan Hare, Translational Scientist, The Francis Crick Institute
Oct 1610:00
Conference pass
Title TBC
Cancer & Therapeutic Vaccines
Session led by: 
Oct 1610:15
Conference pass
VFI Adjuvant Portfolio
Supply & Logistics
Oct 1610:30
Conference pass
RNAbox: A continuous RNA production platform process-in-a-box for rapid disease-agnostic RNA vaccine & therapeutic development and mass-manufacturing at high-quality and low-cost
Manufacturing Technologies
Oct 1610:30
Conference pass
Systemic and Shifting Global Market Stressors: Navigating Funding, Partnerships and Innovation in a Volatile Era
Partnerships & Access
- Systemic investment barriers to vaccine investment; high R&D costs, uncertain returns, market distortions, and socio-political linked demand uncertainty impact vaccine investment
- The impacts of fiscal austerity, the rise of transactional aid, and shifting priorities on transitional funding methods, partnerships and equitable access
- How to incentivise R&D in this evolving landscape to prevent innovation stalling and accelerate breakthroughs
- Exploring sustainable, scalable solutions to fill the gap left by declining public-sector funding; blended finance, pooled procurement, and value-based pricing
- Real world case studies: GAVI’s AMC, CEPI’s equity clauses, pharma-NGO coalitions
Ankur Mutreja, Director of Strategy Partnerships and Communications, South Asia-PATH
Oct 1610:30
Conference pass
BioNTech’s oncology pipeline: combining cancer vaccines with immunomodulators & targeted therapies
Cancer & Therapeutic Vaccines
Oct 1610:45
Conference pass
Title TBC
Supply & Logistics
Mads Skovvang, Manager, Commercial Supply Chain - Europe, World Courier
Oct 1610:45
Conference pass
Shigella Clinical Updates
Neglected Diseases & Global Health
Simona Rondini, Head Bacterial Projects and Senior Project Leader, GSK Vaccines
Oct 1611:00
Conference pass
Irradiation technologies for vaccine manufacturing
Manufacturing Technologies
Oct 1611:00
Conference pass
Bridging the gaps: Overcoming the remaining challenges in vaccine development for global health
Neglected Diseases & Global Health
- The role of epidemiology and disease prevalence data in setting priorities for vaccine development
- Navigating uncertainty: how to make evidence-based decisions when data is scarce or incomplete
- What we can learn from successful (and stalled) vaccine efforts across other global health diseases
- How innovation in immunogenicity and correlates of protection can accelerate progress in emerging and respiratory disease threats
Oct 1611:30
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1612:30
Conference pass
Clinical Trials Track Chair
Clinical Trials
Oct 1612:30
Conference pass
Showcasing & Utilising Established Challenge Models: Improving A Malaria Vaccine Candidate Using CHIM
Clinical Trials
Oct 1612:30
Conference pass
Strategic Partnerships in Vaccine Development: Platforms vs. Products
Partnerships & Access
- How are biopharma partnerships evolving?
- Evaluating technology-led vs. product-led partnership models
- Bridging academic immunology discoveries to biotech commercialisation
- Balancing partner interests in multi-stakeholder vaccine projects
- Structuring deals and best practices in securing platform technology partnerships
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford - Oxford Vaccine Group
Oct 1612:30
Conference pass
Panel: End-to-end Vaccine Supply Chain in Africa for Disease Immunization and Building Autonomy
Supply & Logistics
Oct 1612:30
Conference pass
AI-Driven Neoantigen Selection: Technology Advancements and Clinical Applications
Cancer & Therapeutic Vaccines
Oct 1612:45
Conference pass
Combination Vaccines as Equity Accelerators: Can Co-Administration Ease the Burden on Health Systems?
Neglected Diseases & Global Health
- Exploring the scientific, clinical, and operational benefits of vaccine co-formulation for equity, efficacy, and broader protection – what diseases cluster geographically (e.g., schiso & dengue?)
- Challenges in developing compatible combination vaccines; ensuring immunogenic compatibility
- Case study: Measles/MPOX in Gaza, heat-stable malaria/hookworm combos, mRNA vaccine co-administration and implications for future NTD combinations
- Health system resilience, reducing immunisation burdens to enhance vaccine access in resource-limited settings
- Economic insights and equity considerations from LMIC perspective – how can combination vaccines cut delivery costs by 30-40%?
Kutub Mahmood, Scientific Director, PATH
Oct 1613:00
Conference pass
EVX-01 Personalized Neoantigen Vaccine: One-Year Insights from a Phase 2 Cancer Study
Cancer & Therapeutic Vaccines
Session led by:
Oct 1613:30
Conference pass
Showcasing & Utilising Established Challenge Models: What can we achieve with these?
Clinical Trials
Oct 1613:30
Conference pass
Digital twins for vaccine manufacturing: a modelling pathway towards preparedness and fast response.
Supply & Logistics
- What is a digital twin, and how can it improve decision-making across vaccine manufacturing?
- Real-world example: key components of a digital twin model and the types of decisions it can support
- Scenario planning for outbreak preparedness and agile response: how digital twins enable forward-looking strategies both for manufacturers as well as prepardness agencies
- Industry and government perspectives: where digital twins deliver value across stakeholders, and what challenges remain
Gemma Lahuerta Buira, Parenteral Development Director, LABORATORIO REIG JOFRE, S.A.
Oct 1613:30
Conference pass
DNA medicine candidate INO-3107, an immunotherapy for RRP, a rare-HPV related disease
Cancer & Therapeutic Vaccines
Oct 1613:45
Conference pass
Regulating Personalised mRNA Cancer Immunotherapies: AI Innovation vs Regulation, Global Impact and Industry Readiness
Cancer & Therapeutic Vaccines
- How will MHRA’s classification of these therapies as ATMPs impact global regulatory alignment?
- What are the key risks of AI performance drift and bias in personalised therapy development?
- How will classifying algorithms as SaMDs shifting AI-driven selection to an IVD regulatory framework disrupt existing trial, manufacturing and quality control models? Should AI-driven neoantigen selection be classified under IVD regulations, or should it remain part of GMP-regulated manufacturing?
- What industry best practices exist for balancing regulatory compliance with the rapid release of individualised therapies?
Oct 1613:45
Conference pass
Vaccine Policy in Polycrisis: Sustaining Immunisation Access Under Pressure
Neglected Diseases & Global Health
- Translating WHO guidelines into rapid, flexible decision-making
- Effective health system triage during chronic collapse
- Maintaining vaccine funding amid geopolitical disruptions: insights from EU budget cuts, US-Gulf state bridging finance, and UAE crisis funding mechanisms.
- Practical innovations in crisis vaccine delivery
- Accelerating R&D and policy adaptations under crisis conditions
Luigi Bonfatti, Executive Advisor, RVMC (Regionalized Vaccine Manufacturing Collaborative)
Oct 1614:00
Conference pass
Strengthening Partnerships and Local Networks for Infectious Disease Trials
Partnerships & Access
- Identifying and leveraging local partnerships for clinical trials in endemic regions
- Local vs. Global Execution: Can we effectively run endemic country clinical trials, or do we need new frameworks?
- How do geopolitical factors impact trial execution and long-term sustainability?
- Evaluating the effectiveness of existing networks for global health collaborations; Are current partnerships enough, or do we need new collaborative models?
- How can industry and academia ensure equitable, lasting infrastructure for future trials? Strategies for building sustainable partnerships in resource limited settings
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
Oct 1614:45
Conference pass
Exhibition & Networking Break
Exhibition & Networking
Join us in the Exhibition Hall for1-2-1 partnering and refreshments
Oct 1615:00
Conference pass
Life-Course Immunisation: Are Combination Vaccines the Only Viable Path Forward for Adults?
Keynotes
- Evaluating the economic and societal case for routine adult and life-course immunisation,
- What next-generation combination vaccines are approaching approval, and when will health systems realistically adopt them?
- Will standalone new vaccines remain viable, or is the future exclusively in combination vaccines?
- Strategies for integrating novel antigens into existing vaccine presentations and delivery systems
- Policy, procurement, and health system strategies to sustainably deliver true life-course immunisation.
Annaliesa Anderson, SVP and Head, Vaccine R&D, PFIZER
Jerome Kim, Director General, ivi
Raches Ella, Head - Business Development & Advocacy, Bharat Biotech International Limited
last published: 18/Jul/25 11:15 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events